Coherus BioSciences (CHRS) Reports Q3 Loss of $1.79
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.48 +6.47%
EPS Growth %: +23.5%
Financial Fact:
Income/(loss) from operations: 27.38M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +23.5%
Financial Fact:
Income/(loss) from operations: 27.38M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($1.79), versus ($6.23) reported last year. Revenue for the quarter came in at $16.1 million, versus $500 thousand reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- JPMorgan Upgrades Sika AG (SIKA:SW) (SKFOF) to Neutral
- Vail Resorts taps bankers for potential activist defense, Semafor reports
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
